Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
I have followed the various articles, reports and correspondence in
the BMJ on this subject.
I am very surprised that none of the contributors have mentioned the
place of COX II inhibitors in the substantial minority of the population
who are intollerant of Aspirin and traditional COX II inhibitor NSAIDs.
In our clinic we see these patients frequently. The reaction to
NSAIDs is anything from an exacerbation of urticaria (30% of CIU),
angioedema, wheeze, through to full anaphylactoid reactions and cardiac
arrest.
The above group of patients are often tollerant of COX II inhibitors
and their use for analgesic and anti-inflammatory purposes is extremely
usefull. At our clinic we offer an oral challenge to celecoxib in these
patients.
Yours faithfully,
Marise McQueen, MB ChB, MRCGP, FFARCS.
Competing interests:
None declared
Competing interests:
No competing interests
20 June 2006
Marise A McQueen
Clinical Assistant at West of Scotland Anaphylaxis Service.
COX II inhibitors have a unique indication.
I have followed the various articles, reports and correspondence in
the BMJ on this subject.
I am very surprised that none of the contributors have mentioned the
place of COX II inhibitors in the substantial minority of the population
who are intollerant of Aspirin and traditional COX II inhibitor NSAIDs.
In our clinic we see these patients frequently. The reaction to
NSAIDs is anything from an exacerbation of urticaria (30% of CIU),
angioedema, wheeze, through to full anaphylactoid reactions and cardiac
arrest.
The above group of patients are often tollerant of COX II inhibitors
and their use for analgesic and anti-inflammatory purposes is extremely
usefull. At our clinic we offer an oral challenge to celecoxib in these
patients.
Yours faithfully,
Marise McQueen, MB ChB, MRCGP, FFARCS.
Competing interests:
None declared
Competing interests: No competing interests